Avandra Health, a federated network for medical imaging and clinical data, announced on Sunday that it has acquired healthcare technology company DatCard Systems and medical equipment manufacturer Sorna Corporation.
With these acquisitions, Avandra aims to build a leading medical imaging platform providing imaging data to improve patient care across clinical and research applications.
The two additions combine the complementary capabilities of clinical data sharing between providers (DatCard and Sorna), with Avandra's de-identified patient data aggregation platform to fuel medical research, AI development, and clinical innovation.
DatCard Systems and Sorna Corporation will continue to operate as independent companies under the Avandra brand umbrella.
Ryan Tarzy, Avandra Health CEO, said: "By bringing together DatCard, Sorna, and Avandra, we're creating the industry's first comprehensive medical imaging platform that serves both immediate patient care needs and long-term research innovation. This combination enables us to unlock the full potential of medical imaging to transform healthcare delivery and accelerate life-saving research, while continuously improving the tools and support that clinicians depend on daily. Our customers can be confident that the products and services from DatCard and Sorna that they rely on every day will continue without interruption -- delivered by the same teams, and with the same commitment to outstanding service."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA